Clinical Trial Update: Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

A Phase III trial evaluating camrelizumab in combination with chemotherapy for recurrent/metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: UNKNOWN